Retapamulin

Summary

Retapamulin (CHEMBL1658) is an approved small molecule (ATC D06AX13); indicated across 4 conditions including impetigo and staphylococcal infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06AX13
• Indications: 4 conditions
• Clinical trials: 12
• Chemistry: 517.8 Da · C30H47NO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1658
Name	Retapamulin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6918462
ATC	D06AX13
Molecular formula	C30H47NO4S
Molecular weight	517.8
InChIKey	STZYTFJPGGDRJD-FJJJPKKESA-N

SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C

IUPAC name: [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate

Also known as: Altabax, Altargo, NSC-759885, Retapamulin, Retapamulina, Retapamuline, Sb 275833, SB-275833, SB275833, Retapaulin, RETAPAMULIN, retapamulin

Patent coverage: 18 distinct patent families (21 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
impetigo	4	MONDO:0004592	EFO:1000714
staphylococcal infection	4	MONDO:0024313	EFO:1001849

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
staphylococcus aureus infection	2	MONDO:0005545	EFO:0005681

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE4	4
Not specified	3
PHASE3	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00856089	PHASE4	WITHDRAWN	Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
NCT01064947	PHASE4	COMPLETED	Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
NCT01126268	PHASE4	COMPLETED	Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
NCT01461668	PHASE4	COMPLETED	Retapamulin for Reducing MRSA Nasal Carriage
NCT01397461	PHASE3	COMPLETED	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT03304873	PHASE3	COMPLETED	Retapamulin as a Decolonizing Agent for MRSA
NCT00539994	PHASE2	COMPLETED	Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
NCT00903279	PHASE2	WITHDRAWN	Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery
NCT01812382	PHASE1	COMPLETED	Retapamulin Microdialysis Feasibility Study
NCT01153828	Not specified	COMPLETED	EU PV for Retapamulin-Prescribing
NCT01153880	Not specified	COMPLETED	United States Pharmacovigilence Retapamulin-Prescribing
NCT01591785	Not specified	COMPLETED	Treatment of Staphylococcus Aureus Colonization in Hand Eczema

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).